What is DNA Script?
Founded in 2014, DNA Script is a life sciences technology firm revolutionizing the design and manufacture of nucleic acids. The company's proprietary Enzymatic DNA Synthesis (EDS) technology offers a faster, more powerful, and versatile alternative to traditional chemical synthesis methods. By enabling DNA synthesis directly within laboratories via its SYNTAX System, DNA Script empowers researchers with unprecedented control and autonomy, aiming to transform the pace and scope of life sciences research and development.
How much funding has DNA Script raised?
DNA Script has raised a total of $302M across 3 funding rounds:
Series A
$13M
Series B
$89M
Series C
$200M
Series A (2017): $13M with participation from Illumina Ventures
Series B (2020): $89M led by Agilent Technologies, Life Sciences Partners, Bpifrance Large Venture Fund, Illumina Ventures, Danaher Life Sciences, Casdin Capital, and M Ventures
Series C (2021): $200M supported by Catalio Capital Management and Coatue
Key Investors in DNA Script
Illumina Ventures
Illumina Ventures is a venture capital firm focused on genomics and precision health, aiming to foster innovation in life sciences and translate investments into advancements in human health and biopharmaceutical development.
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing innovative laboratory solutions and instruments to researchers and organizations worldwide.
Life Sciences Partners
Life Sciences Partners (LSP) is a European venture capital firm specializing in investments in the life sciences sector, supporting companies from early-stage development through to commercialization.
What's next for DNA Script?
The substantial enterprise-level funding positions DNA Script for significant scaling and further innovation in the rapidly evolving biotechnology sector. This capital infusion is expected to accelerate the commercialization of its EDS technology, expand its global reach, and deepen its research and development efforts. The company's strategic investments signal a commitment to solidifying its leadership in synthetic biology and enabling next-generation genomic applications, from drug discovery to diagnostics.
See full DNA Script company page
